TB-500 (10 mg Vial) Dosage Protocol

Plan based on an 8–16 week daily protocol with gradual titration.

• Peptide Vials (TB‑500, 10 mg each):
  • 8 weeks: approximately 4 vials required
  • 12 weeks: approximately 7 vials required
  • 16 weeks: approximately 10 vials required
• Insulin Syringes (U‑100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
• Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • 8 weeks (4 vials): 12 mL — 2 bottles required (10 mL each)
  • 12 weeks (7 vials): 21 mL — 3 bottles required (10 mL each)
  • 16 weeks (10 vials): 30 mL — 3 bottles required (10 mL each)
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs — 2 boxes required (100 swabs each)
  • 12 weeks: 168 swabs — 2 boxes required (100 swabs each)
  • 16 weeks: 224 swabs — 3 boxes required (100 swabs each)

TB-500 10 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

Practice preparing this vial with the verified strength and final volume from this protocol.

• Reconstitute: Add 3.0 mL bacteriostatic water for approximately 3.33 mg/mL.
• Calculation range: 500 mcg (0.5 mg) to 1,000 mcg (1 mg) per administration in the displayed community-reported schedule.
• U-100 conversion: 1 unit = 0.01 mL = approximately 33.3 mcg; 15 units is 0.15 mL or 500 mcg.
• Identity check: Confirm the exact peptide sequence and molecular mass on the lot-specific documentation because TB-500 and full-length thymosin beta-4 are not interchangeable research materials.^[1][14]

Published analytical literature identifies TB-500 as the N-terminally acetylated seven-amino-acid fragment Ac-LKKTETQ derived from thymosin beta-4.^[1][2] Direct human dose-finding studies of this TB-500 fragment were not identified. Human studies of full-length or recombinant thymosin beta-4 used different materials, routes, and amounts, so they cannot validate the subcutaneous calculation schedule on this page.^[7][8]

TB-500 naming is inconsistent across research and commercial contexts. Analytical studies identified this synthetic peptide as Ac-LKKTETQ, an acetylated fragment corresponding to residues 17-23 of the 43-amino-acid thymosin beta-4 protein.^[1][2] The fragment and full-length thymosin beta-4 share a biological relationship, but they are different molecules with different molecular weights, pharmacokinetics, and study histories.

That distinction matters when reading a TB-500 dosage page. Published human studies have examined intravenous recombinant or synthetic full-length thymosin beta-4, and ophthalmic thymosin beta-4 has also reached controlled trials.^[7][8][9] Those findings cannot be transferred to a reconstituted 10 mg TB-500 vial without confirming the sequence, formulation, route, and concentration. Review the product label and lot-specific certificate before applying any literature to the material in hand.^[14]

The 10 mg vial changes the concentration and syringe markings, not the evidence behind the displayed schedule. With a final volume of 3.0 mL, the concentration is:

10 mg ÷ 3.0 mL = 3.333 mg/mL = 3,333 mcg/mL.

A U-100 insulin syringe has 100 volume markings per mL, so one unit is 0.01 mL. At 3,333 mcg/mL, one unit contains approximately 33.33 mcg. The displayed rows follow the same formula:

• 500 mcg: 500 ÷ 3,333 = 0.15 mL, or 15 units.
• 600 mcg: 600 ÷ 3,333 = 0.18 mL, or 18 units.
• 750 mcg: 750 ÷ 3,333 = 0.225 mL, displayed as 23 units (0.23 mL) after rounding.
• 1,000 mcg: 1,000 ÷ 3,333 = 0.30 mL, or 30 units.

U-100 units are syringe volume markings. They are not international units of TB-500 activity. Use the concentration from the prepared vial, not the vial strength alone, when checking a syringe conversion.

The primary chart is organized by week so a reader can see mass, volume, syringe units, injection frequency, and cycle length together. The 500-1,000 mcg range is presented as community-reported use. This dosing schedule should not be described as a standard, recommended, or clinically validated human regimen.

Published TB-500 studies are principally analytical, anti-doping, animal, or in-vitro investigations. One equine detection study administered a single 10 mg dose to horses to identify the parent peptide and metabolites, not to establish a therapeutic schedule for people.^[2] A 2024 metabolism study evaluated TB-500 in human serum systems, rats, and fibroblast assays; it did not test the chart’s staged human regimen.^[3]

For vial planning, the displayed 12-week sequence uses 64.4 mg in total: 7 mg in weeks 1-2, 8.4 mg in weeks 3-4, 21 mg in weeks 5-8, and 28 mg in weeks 9-12. That requires seven 10 mg vials when whole-vial purchasing is counted. Extending the same final row through week 16 would bring the calculated total to 92.4 mg and require ten vials.

The supplier page describes the 10 mg product as a lyophilized powder and lists frozen storage at -20 °C (-4 °F) for the unopened material.^[14] The page does not publish a product-specific reconstituted stability period. Do not infer a universal discard date from the vial strength.

• Before reconstitution: Keep the sealed lyophilized vial at the product-label temperature, protected from moisture and repeated temperature cycling.
• After preparation: Label the vial clearly, refrigerate at 2-8 °C (36-46 °F), protect it from light, and follow verified lot-specific handling instructions if they differ.
• Inspection: Do not use a prepared research solution that shows unexpected particles, discoloration, leakage, or loss of container integrity.
• Documentation: Record the final volume, calculated concentration, preparation date, lot number, and storage conditions.

The LKKTETQ region of thymosin beta-4 is associated with actin-related cell migration. Experimental work found that the seven-amino-acid actin-binding motif was important for endothelial movement, vessel sprouting, and formation of new blood vessels in cell and tissue models.^[4] Separate studies of full-length thymosin beta-4 reported keratinocyte migration, collagen deposition, angiogenesis, and faster closure after tissue injury in rat wound models.^[5] Other cell studies observed tube formation and vascular sprouting after thymosin beta-4 exposure.^[6]

These findings explain why the peptide is discussed in tissue repair, healing, and recovery research, but they do not prove that a reconstituted injection produces the same effects in humans. A recent metabolism study also found that one metabolite, Ac-LKKTE, showed wound-healing activity in a fibroblast assay while the parent compound’s biological effects remained incompletely documented.^[3] Mechanistic plausibility is not the same as clinical efficacy.

• Compound identification: Mass-spectrometry studies identify Ac-LKKTETQ and its metabolites in analytical, equine, and anti-doping contexts.^[1][2][10]
• Cell and animal findings: Wound repair, migration, and angiogenesis findings largely involve full-length thymosin beta-4 or closely related fragments in cells, explants, rats, or horses.^[4][5][6]
• Human research: Phase 1 studies examined intravenous synthetic or recombinant full-length thymosin beta-4. They do not establish a subcutaneous TB-500 dose.^[7][8]
• Other formulations: Ophthalmic thymosin beta-4 has been studied in dry-eye trials, a route and formulation that cannot validate an injectable fragment schedule.^[9]
• Missing evidence: No controlled human trial identified for this review tested the displayed 500-1,000 mcg subcutaneous TB-500 schedule, the 10 mg vial preparation, or an 8-16 week course.

Safety findings for full-length thymosin beta-4 should not be presented as TB-500 safety data. Healthy-volunteer studies used intravenous full-length or recombinant thymosin beta-4 under monitored trial conditions.^[7][8] They do not resolve the purity, sterility, immunogenicity, local reaction, interaction, or long-term risk questions associated with independently prepared TB-500 research material.

The 2026 World Anti-Doping Agency Prohibited List names thymosin beta-4 and its derivatives, including TB-500, under growth factors and growth-factor modulators prohibited at all times.^[13] Researchers working in sport-governed settings should check the current list directly because anti-doping rules are updated annually.

Unexpected pain, swelling, redness, fever, neurologic symptoms, allergic symptoms, or changes in the prepared solution are not findings that a dosage calculator can interpret. The page provides measurement and evidence context only, not medical monitoring or treatment guidance.

The route in the chart comes from community descriptions, not a validated TB-500 clinical protocol. General subcutaneous injection literature supports single-use needles, consistent site rotation, and techniques that reduce unintended intramuscular placement and repeated trauma.^[11][12]

• Confirm that the syringe is marked U-100 before using the unit conversions on this page.
• Use a new sterile syringe for each administration and place used sharps in an approved sharps container.
• Clean the vial stopper and preparation surface, allow antiseptic to dry, and avoid touching sterile connection points.
• Rotate sites systematically rather than using the same point repeatedly.
• Record the syringe units and corresponding mL so the measurement can be independently checked.

What is an established human TB-500 dosage?

No clinically established human dose for the Ac-LKKTETQ TB-500 fragment was identified in the reviewed literature. The table is a transparent conversion of community-reported amounts, not a medical recommendation.

How many U-100 units equal 500 mcg from this 10 mg vial?

With 10 mg reconstituted to 3.0 mL, 500 mcg equals 0.15 mL or 15 U-100 syringe units. A different final volume produces different syringe markings.

Is TB-500 the same as thymosin beta-4?

Not necessarily. Published analytical studies describe TB-500 as an acetylated seven-amino-acid fragment of thymosin beta-4, while full-length thymosin beta-4 contains 43 amino acids.^[1] Verify the exact sequence on the lot documentation.

How long does a 10 mg vial last?

It depends on the amount per administration. The vial contains twenty 500 mcg amounts, about thirteen 750 mcg amounts with some remainder, or ten 1,000 mcg amounts. This is vial-yield math, not a duration recommendation.

Why do full-length thymosin beta-4 trials not validate this schedule?

Those trials used a different molecule or formulation, different routes, and different amounts under clinical monitoring.^[7][8][9] Results cannot be transferred by name alone.

Is TB-500 prohibited in competitive sport?

Yes. The 2026 WADA Prohibited List expressly includes thymosin beta-4 and derivatives such as TB-500.^[13]

What are common TB-500 dosing mistakes in research calculations?

Common mistakes include treating U-100 markings as peptide activity units, using vial strength without the final liquid volume, rounding the concentration before calculating, or applying full-length thymosin beta-4 findings to the shorter fragment. The reconstitution guide and unit math above keep those variables explicit.

This page is an educational calculation reference. TB-500 is not FDA-approved for human use, the displayed schedule is not a validated treatment regimen, and the page does not replace medical or institutional research oversight.

• 1
  Drug Testing and Analysis – Synthesis and characterization of the acetylated 17-23 thymosin beta-4 fragment identified in TB-500.

  View Source
• 2
  Journal of Chromatography A – Identification and detection of TB-500 and metabolites in equine samples.

  View Source
• 3
  Journal of Chromatography B – TB-500 metabolism in human serum systems and rats with fibroblast activity screening.

  View Source
• 4
  FASEB Journal – The actin-binding site on thymosin beta-4 promotes angiogenesis in experimental models.

  View Source
• 5
  Journal of Investigative Dermatology – Thymosin beta-4 accelerated repair in a rat full-thickness wound model.

  View Source
• 6
  Angiogenesis – Thymosin beta-4 effects on endothelial differentiation and vascular sprouting.

  View Source
• 7
  Annals of the New York Academy of Sciences – Phase 1 intravenous synthetic full-length thymosin beta-4 study in healthy volunteers.

  View Source
• 8
  Clinical and Translational Science – First-in-human intravenous recombinant thymosin beta-4 study in healthy volunteers.

  View Source
• 9
  Clinical Ophthalmology – Randomized phase 2 ophthalmic thymosin beta-4 study for dry eye.

  View Source
• 10
  Journal of Pharmaceutical and Biomedical Analysis – In-vitro metabolism comparison for TB-500 and other synthetic peptides.

  View Source
• 11
  Diabetes Care – Evaluation of injection angle, skinfold, leakage, and 5 mm needles for subcutaneous delivery.

  View Source
• 12
  Mayo Clinic Proceedings – Evidence-informed recommendations on site rotation, single-use needles, and sharps disposal.

  View Source
• 13
  World Anti-Doping Agency – 2026 Prohibited List naming thymosin beta-4 and derivatives including TB-500.

  View Source
• 14
  Pure Lab Peptides – TB-500 10 mg product identity, lot documentation, and unopened storage information.

  View Source

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.